To evaluate postoperative health resource utilisation and secondary care costs for radical prostatectomy and partial nephrectomy in National Health Service (NHS) hospitals in England, via a comparison of robot-assisted, conventional laparoscopic and open surgical approaches.
Introduction
Robot-assisted surgery (RAS) is a minimally invasive technique used for complex procedures in a growing number of healthcare systems worldwide. RAS is an established therapy across multiple specialties, including gynaecology, cardiothoracics and urology. In the UK, robotic systems are most commonly employed in the removal of bladder, kidney and prostate cancers, according to UK Hospital Episode Statistics (HES) data. A growing body of literature suggests that RAS, as an alternative to conventional open surgery, improves functional outcomes including urinary continence and erectile function after radical prostatectomy [1, 2] , and reduces risk of adverse events and peri-operative blood loss [3, 4] . RAS is associated with a shorter hospital stay [5, 6] and oncological outcomes are similar to those of open surgery [7] .
Since the introduction of RAS in England in 2001, its prevailing use has been in radical prostatectomy for prostate cancer [8] , the most common male cancer in England. Robot-assisted radical prostatectomy (RARP) is recommended by the UK's National Institute for Health and Care Excellence for removal of localized forms of the disease [9] ; in 2013, RAS was used in more than half of surgeries (HES data). In 2005, surgeons in England began conducting robot-assisted partial nephrectomies (RAPNs) for renal cancers [10] , and by 2013 more than one in five surgeries were carried out using the technology. The largest manufacturer of RAS systems, Intuitive Surgical, had provided 55 of its da Vinci â Surgical Systems to UK hospitals by September 2015.
Investment in RAS involves a significant outlay by a hospital, with the systems often costing more than one million pounds and annual service costs reaching hundreds of thousands of pounds; a significant proportion of NHSbased RAS systems were initially (and continue to be) funded by charitable donations and dedicated fundraising [8] . A UK study of the cost-effectiveness of RAS in radical prostatectomy suggested that the higher costs of the approach may be offset by a reduced risk of short-term complications and positive surgical margins, provided that the system is used in at least 150 cases each year [11] . The study also notes that there is a distinct lack of comparable randomized data available to researchers; nevertheless, recent draft national guidance from NHS England, the funding body responsible for overseeing investment in RAS, cautiously recommends the technology for treatment of prostate cancer, albeit with the requirement for further evidence generation regarding long-term outcomes [12] .
In the present study, we investigated secondary health resource utilisation and associated costs after radical prostatectomy and partial nephrectomy for prostate cancer and kidney cancer, respectively, using 'real-world', routinely collected data from English hospitals, with the aim of identifying and quantifying the downstream savings achieved through substituting conventional open and laparoscopic surgeries with RAS. If it can be shown that there are cost savings (via reduced postoperative resource use), this would provide greater evidence that access to RAS in urological cancer surgeries can reap long-term financial benefits for commissioners, and improve patient care.
Patients and Methods

Patients and Data Selection
We used routinely available national HES data from April 2008 to December 2013. The HES database contains information on inpatient admissions, outpatient appointments, and Accident and Emergency department attendances, with more than 12 million new records added each year. It includes private patients treated in NHS hospitals, patients resident outside of England, and care delivered by treatment centres (including those in the independent sector) funded by the NHS (patients treated in the private sector without NHS funding are not covered in the HES data). All NHS hospitals in England are required to contribute to this database. The HES database is managed by the NHS Health and Social Care Information Centre and is available for research without ethics approval. For inpatient admissions, the data available consist of a number of coded records for each admission, which are called 'episodes'. For radical prostatectomy, the study population (men aged ≥18 years) was selected based on a recorded HES episode with the following characteristics (see Appendix S1 for OPCS-4.7 codes):
• ICD-10 primary diagnosis code C61 (malignant neoplasm of prostate) and
• One of OPCS-4.7 procedure codes for radical prostatectomy and either o One of OPCS-4.7 approach codes for RAS or o One of OPCS-4.7 approach codes for conventional laparoscopic surgery or o The absence of a RAS or laparoscopic approach code, signifying an open procedure.
For partial nephrectomy, the study population (men and women aged ≥18 years) was selected based on a recorded HES episode with the following characteristics:
Study Design
A retrospective, longitudinal, open-cohort design was used. Each patient's observation period extended from the day of hospital discharge up to 1 080 days. The resource use and clinical outcomes of patients in the short-term postoperative period (i.e. adverse events such as blood loss and length of hospital stay at intervention) have been studied extensively elsewhere [10, 13] ; therefore, we focus specifically on the lesser-studied downstream resource use and costs associated with these procedures, starting in the period immediately after hospital discharge.
All post-intervention episodes were filtered using expert clinical guidance to remove activity considered unlikely to be related to the intervention and/or the primary indication. The following secondary care resources were examined in the post-intervention period: inpatient admissions, outpatient visits and number of hospital bed-days and excess bed-days (defined as days spent in hospital beyond the 'upper trim point', or expected length-of-stay, for the Hospital Resource Group (HRG) assigned to the episode [14] ).
Inpatient, outpatient and total costs in the post-intervention period are based on NHS 'Payment by Results' HRG tariffs for 2013. For any HRGs discontinued before 2013, the most recently available tariff was inflated to 2013 values using the Hospital and Community Health Services Index [15] . Excess bed-days are reimbursed separately from the HRG tariff, which sets a fixed price for a length-of-stay up to and including the upper trim point; they are therefore of additional importance to commissioners in measuring cost impact.
Statistical Analysis
Descriptive analysis was conducted to summarize patient characteristics. Means were used to describe continuous variables, and frequency and proportions were used to describe categorical variables. Comparisons between open surgery and RAS are shown (laparoscopic surgery is a valid comparator for RAS, but not necessarily the most appropriate comparator, and is therefore not used for direct comparison in the present study. Nonetheless, results for laparoscopic surgery are shown in the results).
Data relating to health resource use (admissions, costs, etc.) are often non-normally distributed, as they are always positive values, have a large proportion of zero values (i.e. no admissions), and are often highly skewed as a result of disproportionately large resource use from a small number of outlying patients. It was therefore appropriate to apply a nonparametric test when analysing significant differences between surgical approaches. Differences for continuous variables were therefore estimated using Wilcoxon rank-sum (Mann-Whitney) tests; comparisons for categorical variables were made using chi-squared tests.
The results below present health resource utilisation at 360 and 1 080 days post-intervention episode. Utilisation during the intervention hospital stay was excluded from the analysis. STATA â 13 was used for all statistical analyses and hypothesis testing [16] .
Results
Radical Prostatectomy
Trends in radical prostatectomy
Between April 2008 and December 2013, the number of RARP procedures as a proportion of all radical prostatectomies increased from 15% to 51%. The use of laparoscopic radical prostatectomy (LRP) has remained relatively stable across the period (range 23-32%), suggesting that RARP is more often a substitute for open radical prostatectomy (ORP) procedures.
Patient characteristics
A total of 23 735 patients met the inclusion criteria: 19 480 (at 360 days) and 10 565 (at 1 080 days) patients were followed-up over the study period. Patients undergoing RARP were significantly younger than those undergoing ORP and LRP (mean age 62.1 vs 63.2 and 62.7 years, respectively) although the magnitude of the difference was not substantial. Patient comorbidities (quantified using the Elixhauser Index) were no different for any of the three patient groups (index score range 1.54-1.58). Just over onethird of procedures were robot-assisted; of the remainder, 29% were LRPs and 38% were ORPs. A total of 417 480 patient observations (inpatient and outpatient) were recorded in the postoperative period. outpatient and Accident and Emergency department) were recorded within or after the intervention period. Table 3 summarizes health resource utilisation at 360 and 1 080 days after surgery. On average, individuals experienced a further 0.72 inpatient admissions within 360 days after surgery for OPN compared with 0.28 for RAPN, a significant difference of À0.44 (P = 0.029). The number of hospital bed-days for patients undergoing OPN was also significantly higher (1.31 vs 0.40; P = 0.040); excess bed-days were reduced, albeit nonsignificantly (0.14 vs 0.00; P = 0.134). The number of outpatient appointments within 360 days was marginally lower for patients in the RAPN group (5.31 vs 5.46; P = 0.881). The relationship of LPN resource utilisation to that of RAPN and OPN procedures was highly similar to that seen in radical prostatectomy, with average levels approximately halfway between those of the two comparator procedure typeswith the exception of outpatient appointments, for which a substantially lower average rate was seen (4.96 vs 5.46 and 5.31 for OPN and RAPN, respectively).
Health resource utilisation
As a result of the low patient sample size at 1 080 days, differences between OPN and RAPN were empirically but not statistically significantly different. For patients undergoing OPN 2.46 inpatient admissions were recorded within 1 080 days of discharge, compared with 0.92 for RAPN, a difference of À1.54 (P = 0.630). The number of hospital bed-days for patients undergoing OPN was also higher (2.80 vs 1.08; P = 0.313), as was the number of excess bed-days (0.35 vs 0.00; P = 0.379). The number of outpatient appointments within 360 days was also lower for patients undergoing RAPN (13.44 vs 12.71; P = 0.681). Results for LPN were more mixed than those seen at 360 days: numbers of inpatient admissions and excess bed-days lay at the midpoint between those for OPN and RAPN, the number of bed-days was marginally higher than that for both comparators and the number of outpatient appointments was marginally lower. Table 4 summarizes the average total costs and for specific cost drivers at 360 and 1 080 days after the procedure. On average, inpatient admission costs within 360 days postintervention were £823.10 for OPN, against £317.19 for RAPN (P = 0.019). The number of outpatient appointments, however, was significantly higher for the RAPN group (£418.82 vs £461.77; P = 0.039). In total, patients in the OPN group incurred £1241.93 in costs related to their intervention within 360 days of discharge; those in the RAPN group incurred £778.96 in costs in the same period (P = 0.843). Over the 1-year period, each patient undergoing RAPN incurred £462.97 less in health resource use than a patient in the OPN group. LPN procedures followed the pattern seen in resource use, with total costs lying at the midpoint between those of OPN and RAPN.
Healthcare costs
On average, inpatient admission costs within 1 080 days after surgery were £1837.58 for OPN, compared with £1109.29 for RAPN (P = 0.560). In contrast to the 360-day period, outpatient appointment costs were marginally lower for patients in the RAPN group at 1 080 days (£1051.01 vs £1012.83; P = 0.564). In total, patients in the OPN group incurred £2888.60 in costs related to their intervention within 1 080 days of discharge; patients in the RAPN group recorded £2122.13 in costs in the same period (P = 0.481). Over the 3-year period, each patient undergoing RAPN incurred £766.47 less in health resource use than a patient undergoing OPN. Once again, patients undergoing LPN incurred total costs approximately halfway between those of patients undergoing OPN and RAPN.
Discussion
The present analysis suggests that there are substantial longterm savings associated with RAS when compared with open and conventional laparoscopic approaches; these are achieved through reduced inpatient admissions, fewer days spent in hospital and fewer outpatient visits. Significant savings can be seen within 1 year after surgery, suggesting a reduction in short-term complications; however, a substantially greater benefit is realised by 3 years after surgery, suggesting that patients also enjoy improved long-term clinical outcomes, with a sustained reduction in demand for health services.
The implications of these findings for the NHS are significant. The purchase and maintenance of a RAS system is substantial, and evidence of its cost-effectiveness is vital to justify the expense for commissioners. Peri-operative complications and poor clinical outcomes are a significant source of health-related quality of life (HRQoL) loss among patients undergoing cancer surgeries [17, 18] . Relative to open surgery, RAS is often associated with reduced positive surgical margins, particularly for radical prostatectomy, and fewer adverse events, all of which contribute to improved patient outcomes and reduced impact on HRQoL. This work suggests that RAS also presents downstream cost savings, making the economic case for RAS compelling for commissioners.
As a result of its relative infancy in NHS hospitals, we identified just 24 RAPN procedures with sufficient follow-up to conduct a 1 080-day analysis. Our results in partial nephrectomy should therefore be seen as indicative rather than statistically conclusive; the revisiting of this analysis in subsequent years, when a greater volume of procedures has a sufficient follow-up period, is recommended. Much is made in the wider literature of the 'learning curve' in RAS, and the relationship between surgical volume and outcomes [19] [20] [21] ; given that our data cover this period of learning for many NHS hospitals, a subsequent analysis of volume effects on patient outcomes would be worthwhile.
Owing to the nature of our methodology, patients were not randomly assigned to a surgical approach, and nor was there a random selection into surgery vs alternative management (e.g. radiotherapy, active surveillance). As a result, patient selection bias might be a limitation of the present study. In addition, patient outcomes may be confounded by other factors not limited to surgical approach; for instance, patients undergoing RAS are more likely to live in areas of relatively low deprivation, as a result of a concentration of machines in higher-income areas of England [22] . Any difference in outcomes should therefore be considered alongside environmental and demographic influences. We would suggest a future expansion of the present study to incorporate patient-level factors in predicting resource use and costs after surgery.
HES data is a nationwide, mandatory dataset covering all patients treated in NHS hospitals, and therefore benefits from being non-discriminatory in terms of geographic and demographic dispersion of the patient population (with the exception of a small cohort managed in the private sector); however, the present analysis of postoperative complications and clinical outcomes was restricted because of the limitations of our data. Postoperative complications are poorly coded in HES data [23] : only 0.13% of ORP procedures contained a recorded blood transfusion, while results from wider literature place transfusion rates closer to 30% [10] . Estimates of functional outcomes, such as urinary incontinence and erectile dysfunction, were limited to recorded episodesmost likely within an outpatient settingrelating to these conditions; however, diagnosis coding is not mandatory in the HES outpatient data set [24] . The incidence of these conditions would therefore be biased downwards if based on outpatient volume alone. Furthermore, these conditions are often managed in primary care; only those patients considered to be at high risk, or electing to undergo invasive treatment, are likely to appear in the HES dataset [25, 26] . The level of follow-up for these complications is also highly dependent on patient beliefs regarding surgical outcomes [17, 27] . It is possible that follow-up treatment is more indicative of centre-specific management of patient expectations than of tangible differences in functional outcomes.
Given the substantial cost differential between RAS and open surgeries at 1 080 days, it would be appropriate to explore (where possible) the nature of specific cost drivers, starting from the intervention itself, in future work. Specifically, proxy measures of oncological outcomes, such as recording of a malignant diagnosis in subsequent years, or radiotherapy and chemotherapy visits, may shed light on the clinical effectiveness of RAS in NHS hospitals.
Our methodology uses a 'top-down' approach to costing, referencing published national tariffs to estimate 'true' costs. As a result, we were reliant on these tariffs in determining the cost differential of the three procedure types. Payment by Results tariffs are derived from the average unit costs of NHS providers, and are therefore expected to correlate with the actual costs of care; however, in the years covered by the present analysis, providers were not reimbursed based on their use of RAS: in radical prostatectomy, patients were differentiated only by the presence of clinical complications and/or comorbidities; in partial nephrectomy, surgeries were (and continue to be) costed based on an open or laparoscopic approach, of which RAS was assigned broadly equally between the two. This results in RAS having a lower average tariff compared with conventional laparoscopic surgery in partial nephrectomy.
A new HRG covering major robot-assisted and bladder neck procedures has been introduced for the 2015/2016 national tariff [28] , and the incorporation of consumables costscurrently reimbursed through locally negotiated tariffs as part of the 'high cost device' listis proposed for the 2016/2017 national tariff [29] . Our hope for future work is that these changes may allow the calculation of an accurate net savings estimate. Meanwhile, we have limited our focus to the downstream costs of RARP and RAPN; combined with a lack of clinical outcome measures, the study falls short of a full cost-effectiveness study. Nevertheless, the magnitude of the savings suggest that the argument for RAS may prove to be both clinically and financially persuasive to those commissioners considering making an investment in the technology.
In conclusion, the present study aimed to fill an evidence gap by using real-world observational data to assess the downstream costs associated with RAS, laparoscopic and open surgical approaches for the treatment of two common cancers in which RAS is used in England. Our analysis suggests that there are substantial savings associated with RAS when compared with open and laparoscopic interventions. While other studies report reductions in the length-of-stay associated with the actual intervention, our work extends these analyses to indicate that there are substantial and statistically significant savings to be made in the three years after surgery.
